Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Otsuka Holdings Co., Ltd.
  6. Summary
    4578   JP3188220002

OTSUKA HOLDINGS CO., LTD.

(4578)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
05/10/2021 05/11/2021 05/12/2021 05/13/2021 05/14/2021 Date
4384 4280 4248 4218 4389 Last
624200 879600 753600 779900 1084500 Volume
+2.02% -2.37% -0.75% -0.71% +4.05% Change
Financials
Sales 2021 1 428 B 13 083 M 13 083 M
Net income 2021 146 B 1 341 M 1 341 M
Net cash position 2021 280 B 2 565 M 2 565 M
P/E ratio 2021 16,0x
Yield 2021 2,29%
Sales 2022 1 468 B 13 448 M 13 448 M
Net income 2022 155 B 1 418 M 1 418 M
Net cash position 2022 348 B 3 192 M 3 192 M
P/E ratio 2022 15,4x
Yield 2022 2,35%
Capitalization 2 380 B 21 758 M 21 801 M
EV / Sales 2021 1,47x
EV / Sales 2022 1,38x
Nbr of Employees 33 151
Free-Float 75,8%
More Financials
Company
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (64.4% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale... 
Sector
Pharmaceuticals
Calendar
06/29
More about the company
Notations Surperformance© of Otsuka Holdings Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about OTSUKA HOLDINGS CO., LTD.
04/28OTSUKA  : Notice Concerning Completion of Payment for Disposal of Treasury Share..
PU
04/14NIKKEI 225  : Down 0.4% Amid Pandemic, Monthly Decline in Private Sector Core Ma..
MT
04/14Otsuka Holdings to Continue Phase III Trial of Brexpiprazole; Shares Fall 5%
MT
04/13H LUNDBECK A/S  : Lundbeck, Otsuka to Push Through With Recruitment in Late-Stag..
MT
04/13OTSUKA  : Decision to continue phase III clinical trial evaluating brexpiprazole..
PU
04/13H LUNDBECK A/S  : Lundbeck and Otsuka announce decision to continue phase III cl..
AQ
03/31Otsuka Partner Akebia Therapeutics Submits Drug Application to US FDA for Chr..
MT
03/31Otsuka Holdings to Issue Shares under Stock Compensation Plan for Employees
MT
03/30ETF PREVIEW : ETFs, Futures Lean Lower as Concerns Over Archegos-Linked Margin C..
MT
03/30AKEBIA THERAPEUTICS  : Submits New Drug Application to FDA For Vadadustat For An..
MT
03/30OTSUKA  : and Akebia Announce Submission of New Drug Application to the FDA for ..
PU
03/30OTSUKA  : appoints Board Members and Audit & Supervisory Board Members (147KB)
PU
03/30OTSUKA  : Notice Concerning Disposal of Treasury Shares as Restricted Stock Comp..
PU
03/30Tosei to Acquire Tokyo Office Building for Nearly $55 Million
MT
03/30Japan Real Estate Investment to Sell Tokyo Office Building to Tosei for $55 M..
MT
More news
News in other languages on OTSUKA HOLDINGS CO., LTD.
05/04IRW-PRESS : Sernova Corp. : Sernova gibt die Berufung der erfahrenen Pharma-Führ..
04/21IRW-PRESS : PsyBio Therapeutics Corp.: PsyBio Therapeutics beruft erfahrene phar..
04/13H. LUNDBECK A/S  : coup d'arrêt
03/23Tokyo plombée par les prises de bénéfices
2020BOURSES ASIATIQUES : Tokyo rassurée, Hong Kong préoccupée
More news
Chart OTSUKA HOLDINGS CO., LTD.
Duration : Period :
Otsuka Holdings Co., Ltd. Technical Analysis Chart | 4578 | JP3188220002 | MarketScreener
Technical analysis trends OTSUKA HOLDINGS CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 4 604,17 JPY
Last Close Price 4 389,00 JPY
Spread / Highest target 23,0%
Spread / Average Target 4,90%
Spread / Lowest Target -4,31%
EPS Revisions
Managers and Directors
NameTitle
Tatsuo Higuchi President, CEO & Representative Director
Yuko Makino Chief Financial Officer & Director
Ichiro Otsuka Chairman
Yukitakeshi Matsutani Independent Outside Director
Yasushi Sekiguchi Independent Outside Director
Sector and Competitors